BOULDER, Colo.--(BUSINESS WIRE)--The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (Nasdaq: INSY). INSYS is an Arizona-based specialty pharmaceutical company.
The Firm’s investigation relates to allegations of off-label drug marketing of one of the Company’s products, a painkiller called Subsys. These allegations were raised in a May 13, 2014, New York Times article titled “Doubts Raised About Off-Label Use of Subsys, a Strong Painkiller.” The article states that while the F.D.A. approved Subsys only for cancer patients who are already using round-the-clock painkillers by oncologists and pain specialists, just 1% of the total Subsys prescriptions are written by oncologists and about half are written by pain specialists. In December of 2014, INSYS confirmed that it had received a subpoena from the U.S. Department of Health and Human Services’ Office of the Inspector General relating to the Company’s sales and marketing practices. Following these announcements, the Company’s stock price fell and multiple class action lawsuits were filed against INSYS.
If you currently own INSYS common stock and are interested in discussing your rights, or have information relating to this investigation, please contact Kip B. Shuman or Rusty E. Glenn toll-free at (866) 569-4531 or email Mr. Shuman at firstname.lastname@example.org or email Mr. Glenn at email@example.com.
The Shuman Law Firm represents investors throughout the nation, concentrating its practice in stockholder litigation.